The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BYOOVIZ (Samsung Bioepis AU Pty Ltd)
Product name
BYOOVIZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
152 (255 working days)
Active ingredients
Ranibizumab
Registration type
NCE/NBE
Indication
BYOOVIZ (ranibizumab) is indicated in adults for:
- the treatment of neovascular (wet) age-related macular degeneration (AMD),
- the treatment of visual impairment due to diabetic macular oedema (DME),
- treatment of proliferative diabetic retinopathy (PDR),
- the treatment of visual impairment due to choroidal neovascularisation (CNV),
- the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM),
- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).